ArticleEuropean journal of hybrid imaging2018
Tc-HDP quantitative SPECT/CT in transthyretin cardiac amyloid and the development of a reference interval for myocardial uptake in the non-affected population.
Article in European journal of hybrid imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Diagnostic accuracy of bone scintigraphy imaging for transthyretin cardiac amyloidosis: systematic review and meta-analysis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Pooled it
- Evolving SPECT-CT technology.The British journal of radiology · 2026Review
- Diagnostic and prognostic value ofEJNMMI reports · 2026Article
- Segmental and global amyloid burden and myocardial mechanics: a multimodality imaging comparison.Journal of medicine and life · 2026Article
- Quantitative SPECT/CT: Technique and Clinical Applications.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- A quantitative SPECT/CT metric for diagnosing transthyretin cardiac amyloidosis: multicenter study on biopsy-confirmed cases.European journal of nuclear medicine and molecular imaging · 2025Article
- Cardiopulmonary Exercise Testing Correlates with Quantitative Left Ventricular [Journal of clinical medicine · 2025Article
- Prognostic implication of DPD quantification in transthyretin cardiac amyloidosis.European heart journal. Cardiovascular Imaging · 2025Article
- The Accuracy of Technetium-99 m Pyrophosphate Imaging in Diagnosing Transthyretin Cardiac Amyloidosis and Its Impact on Patient Management.Current cardiology reports · 2025Review
- Single-center analysis of cardiac amyloidosis using 99m Tc-HMDP imaging for diagnosis and evaluation after tafamidis treatment.Nuclear medicine communications · 2025Article
- DPD Quantification Correlates With Extracellular Volume and Disease Severity in Wild-Type Transthyretin Cardiac Amyloidosis.JACC. Advances · 2024Article
- Lateral Planar Imaging ofAnnals of nuclear cardiology · 2024Article
- Transthyretin amyloid cardiomyopathy disease burden quantified usingJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Diagnostic value of heart-to-mediastinum ratio inJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Diagnostic performance characteristics of planar quantitative and semi-quantitative parameters of TcJournal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Monitoring tafamidis treatment with quantitative SPECT/CT in transthyretin amyloid cardiomyopathy.European heart journal. Cardiovascular Imaging · 2023Article
- Quantitative SPECT/CT Parameters in the Assessment of Transthyretin Cardiac Amyloidosis-A New Dimension of Molecular Imaging.Journal of cardiovascular development and disease · 2023Review
- Hot spot imaging in cardiovascular diseases: an information statement from SNMMI, ASNC, and EANM.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Review
- Quantitative single photon emission computed tomography derived standardized uptake values on 99mTc-PYP scan in patients with suspected ATTR cardiac amyloidosis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background99mTechnetium-HDP (HDP) bone scans differentiate transthyretin (ATTR) cardiac amyloid from other infiltrative myocardial diseases. These scans are not quantitative and are assessed by comparing myocardial uptake to bone. This study examined whether quantitative HDP SPECT/CT can discriminate individuals with cardiac ATTR from the population without this disease.
methodsHDP thoracic xSPECT/CT QUANT (xQUANT) was performed in 29 patients: ATTR cardiac amyloid (
resultsThe cardiac ATTR group had greater HDP myocardial uptake than those with no known infiltrative disease (
conclusionQuantitative SPECT/CT can measure HDP myocardial uptake in individuals with normal hearts and those with cardiac ATTR without recourse to comparison with bone. It enables calculation of a reference interval for HDP myocardial uptake in the population without ATTR cardiac amyloid. Using this reference interval single individuals with cardiac ATTR can be accurately discriminated from the non-affected population. This technique uses a NIST traceable calibration source, potentially allowing development of multicentre clinical decision limits. Its role in disease management warrants further assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.